Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Deferred Taxes (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Deferred Taxes for 5 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes rose 123.76% year-over-year to $3.1 million, compared with a TTM value of $13.0 million through Dec 2025, up 779.67%, and an annual FY2025 reading of $13.0 million, up 779.67% over the prior year.
  • Deferred Taxes was $3.1 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $4.2 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $10.6 million in Q2 2024 and bottomed at -$25.7 million in Q4 2023.
  • Average Deferred Taxes over 5 years is -$1.6 million, with a median of $1.9 million recorded in 2023.
  • The sharpest move saw Deferred Taxes crashed 7487.64% in 2023, then skyrocketed 305.29% in 2024.
  • Year by year, Deferred Taxes stood at $10000.0 in 2021, then skyrocketed by 3380.0% to $348000.0 in 2022, then plummeted by 7487.64% to -$25.7 million in 2023, then skyrocketed by 48.62% to -$13.2 million in 2024, then soared by 123.76% to $3.1 million in 2025.
  • Business Quant data shows Deferred Taxes for KNSA at $3.1 million in Q4 2025, $4.2 million in Q3 2025, and $2.6 million in Q2 2025.